Originally posted at cbsnews.com
October 10, 2012, By Michelle Castillo

An Alzheimer’s drug that was ineffective against preventing decline in cognitive and physical function in patients with late stage Alzheimer’s may prove to help prevent the disease from developing in people who are genetically predisposed to getting it.

Solanezumab from Eli Lilly and gantenerumab from Roche and have been approved for use in a worldwide Alzheimer’s prevention trial. A beta-secretase inhibitor being developed by Eli Lilly is also in consideration for the study.

The study will include 160 patients who have inherited mutations that make them more susceptible to developing early-onset Alzheimer’s. None of them have been diagnosed with dementia. The study will begin in early 2013.

Read the full story at cbsnews.com.